<DOC>
	<DOC>NCT00976950</DOC>
	<brief_summary>The aim of this trial is to evaluate the safety and virological and immunological efficacy of Aptivus in treatment-experienced patients with advanced HIV-1 infection who had developed resistance to more than one protease inhibitor.</brief_summary>
	<brief_title>A Post Marketing Surveillance Study Assessing the Long-term Efficacy and Safety of Aptivus Co-administered With Low-dose Ritonavir in Treatment Experienced Patients With HIV-1 Infection in the Daily Clinical Practice.</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Tipranavir</mesh_term>
	<criteria>Inclusion criteria: 1. HIV1 infected patients who are treatment experienced and infected with HIV1 strains resistant to more than one protease inhibitor and no other therapeutic options. 2. The inclusion criteria follow the same criteria which are describe in the newest SPC Exclusion criteria: The exclusion criteria follow the same criteria which are describe in the newest SPC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>